ArticleOncoTargets and therapy2019
AFP-producing hepatoid adenocarcinoma (HAC) of peritoneum and omentum: a case report and literature review.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- Case Report: AFP-producing gastric hepatoid adenocarcinoma with multiple liver metastases - integrating quantitative imaging and diagnostic decision analysis.Frontiers in oncology · 2026Article
- Spontaneous rupture of hepatic metastasis as the initial presentation of gastric hepatoid adenocarcinoma: a rare case report and literature review.Frontiers in oncology · 2026Article
- Pancreatic hepatoid carcinoma: a case report.AME case reports · 2025Article
- [Primary uterine hepatoid adenocarcinoma: Clinicopathological analysis of 2 cases and literature review].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Review
- Master Regulators of Causal Networks in Intestinal- and Diffuse-Type Gastric Cancer and the Relation to the RNA Virus Infection Pathway.International journal of molecular sciences · 2024Article
- Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study.Cancer reports (Hoboken, N.J.) · 2024Article
- A case report of challenges in distinguishing gastroesophageal junction hepatoid adenocarcinoma from testicular germ cell tumor: Insights for improved diagnosis with gene expression profiling.SAGE open medical case reports · 2024Article
- Hepatoid adenocarcinoma of the stomach with neuroendocrine differentiation: A case report and review of literature.World journal of clinical cases · 2023Article
- Primary Peritoneal Hepatoid Adenocarcinoma Patients Treated by Complete Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Indian journal of surgical oncology · 2023Article
- Disseminated Primary Uterine Hepatoid Adenocarcinoma with α-Fetoprotein Production Demonstrated onDiagnostics (Basel, Switzerland) · 2022Article
- Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report.World journal of clinical cases · 2022Article
- Case Report: A Rare Case of Hepatoid Adenocarcinoma in Stomach and Duodenum Simultaneously.Cancer management and research · 2022Article
- Metachronous Liver Metastasis from Alpha-Fetoprotein-Producing Gastric Cancer Successfully Treated with Capecitabine/Oxaliplatin Combination Chemotherapy.Case reports in surgery · 2022Article
- Interaction between cadherins, vimentin, and V-set and immunoglobulin domain containing 1 in gastric-type hepatocellular carcinoma.Histochemistry and cell biology · 2021Article
- Effectiveness of ultrasound-guided percutaneous transhepatic puncture for the diagnosis of low-level alpha-fetoprotein liver cancer patients.Translational cancer research · 2021Article
- Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments.Frontiers in oncology · 2021Review
- Hepatoid adenocarcinoma of the stomach: Thirteen case reports and review of literature.World journal of clinical cases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoid adenocarcinoma (HAC) is a group of neoplasms with features resembling hepatocellular carcinoma. The stomach is the most commonly affected organ among the reported primary sites. We report the case of a 28-year-old man with chronic hepatitis B and a complaint of abdominal distension. The patient was examined by PET-CT and magnetic resonance imaging (MRI), which showed diffuse thickening of the peritoneum and omentum but no mass was found in the liver. Pathological examination of a biopsy of the omental nodules was consistent with moderately differentiated hepatocellular carcinoma (HCC); thus, a diagnosis of HAC of the peritoneum and omentum was established. The patient received a chemotherapy regimen consisting of oxaliplatin and capecitabine and gained remarkable effects as the AFP level dropped significantly, and the tumour nearly disappeared. When the patient shifted to the standard multikinase inhibitors, Sorafenib or Lenvatinib, both treatments were ineffective. HAC is a heterogeneous group of prognostically unfavourable tumours mimicking the histological appearance of HCC, and the treatment outcomes are still unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.